Ligand Pharmaceuticals Valuation Multiples

Ligand Pharmaceuticals Overview

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Founded

1987

HQ

Employees

68

Website

ligand.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $268M

EBITDA: $123M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Ligand Pharmaceuticals Financials

Ligand Pharmaceuticals reported last 12-month revenue of $268M and EBITDA of $123M.

In the same LTM period, Ligand Pharmaceuticals generated $253M in gross profit, $123M in EBITDA, and $126M in net income.

Ligand Pharmaceuticals P&L

In the most recent fiscal year, Ligand Pharmaceuticals reported revenue of $268M and EBITDA of $197M.

Ligand Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ligand Pharmaceuticals Stock Performance

Ligand Pharmaceuticals has current market cap of $5B, and enterprise value of $4B.

Ligand Pharmaceuticals' stock price is $232.23.

Ligand Pharmaceuticals Valuation Multiples

Ligand Pharmaceuticals trades at 16.2x EV/Revenue multiple, and 35.0x EV/EBITDA.

Ligand Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Ligand Pharmaceuticals has market cap of $5B and EV of $4B.

Equity research analysts estimate Ligand Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ligand Pharmaceuticals has a P/E ratio of 36.8x.

Ligand Pharmaceuticals Margins & Growth Rates

Ligand Pharmaceuticals' revenue in the last 12 month grew by 5%.

Ligand Pharmaceuticals' revenue per employee in the last FY averaged $3.9M, while opex per employee averaged $3.0M for the same period.

Ligand Pharmaceuticals' rule of 40 is 61% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ligand Pharmaceuticals' rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Ligand Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Ligand Pharmaceuticals M&A Activity

Ligand Pharmaceuticals acquired XXX companies to date.

Last acquisition by Ligand Pharmaceuticals was on XXXXXXXX, XXXXX. Ligand Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ligand Pharmaceuticals Investment Activity

Ligand Pharmaceuticals invested in XXX companies to date.

Ligand Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Ligand Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).